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Abstract
The β-adrenergic agonists salbutamol and ephedrine have proven to be effective as therapies for human disorders of the
neuromuscular junction, in particular many subsets of congenital myasthenic syndromes. However, the mechanisms
underlying this clinical benefit are unknown and improved understanding of the effect of adrenergic signalling on the
neuromuscular junction is essential to facilitate the development of more targeted therapies. Here, we investigated the
effect of salbutamol treatment on the neuromuscular junction in the ColQ deficient mouse, a model of end-plate
acetylcholinesterase deficiency. ColQ−/− mice received 7 weeks of daily salbutamol injection, and the effect on muscle
strength and neuromuscular junction morphology was analysed. We show that salbutamol leads to a gradual improvement
in muscle strength in ColQ−/− mice. In addition, the neuromuscular junctions of salbutamol treated mice showed
significant improvements in several postsynaptic morphological defects, including increased synaptic area, acetylcholine
receptor area and density, and extent of postjunctional folds. These changes occurred without alterations in skeletal muscle
fibre size or type. These findings suggest that β-adrenergic agonists lead to functional benefit in the ColQ−/− mouse and to
long-term structural changes at the neuromuscular junction. These effects are primarily at the postsynaptic membrane and
may lead to enhanced neuromuscular transmission.
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Introduction
Motor neurons contact their target muscle fibres at highly
specialised chemical synapses, neuromuscular junctions (NMJ).
The NMJ is the pathogenic target in a wide range of human
diseases, including those resulting fromgenetic defects affecting
a diverse range of proteins which are critical for synaptic
function, the Congenital Myasthenic Syndromes (CMS) (1,2).
CMS arise from mutations affecting presynaptic, synaptic or
postsynaptic proteins at the NMJ, resulting in impairment of
neuromuscular transmission by one or more mechanisms. A
precise molecular classification of CMS subtype is of great
importance for the diagnosis and genetic counselling of patients,
but also to allow administration of effective treatment as
different drugs may be beneficial or deleterious depending on
the CMS subtype (3). Formany subtypes, clinical benefit is gained
from acetylcholinesterase (AChE) inhibitors, which augment the
synaptic response to acetylcholine (ACh) (4). However, AChE
inhibitors are ineffective or even detrimental in Dok7 CMS, slow-
channel CMS, end-plate AChE deficiency and MuSK CMS.
Ephedrine, a sympathomimetic with α- and β-adrenergic
effects, and salbutamol, a selective β2−agonist, have been
successfully used to treat many patients with CMS subtypes
which are not effectively treated by anticholinesterases. These
include those withmutations that cause deficits in Dok-7, Agrin,
MuSK, ALG2, AChR (ε -subunit) and in end-plate AChE deficiency
(5–10). In contrast with the effects of anticholinesterases, the
full effects of these adrenergic treatments are not immediate,
reaching a peak only after several months (5,11). Among the
varied pharmacologic effects of β-agonists, there is considerable
evidence for their numerous effects in regulating skeletal
muscle structure and function, and in exerting an anabolic
effect on skeletal muscle protein metabolism (12–16). These
actions are predominantly mediated through the β2 receptors
(ADBR2), and involve cAMP signalling (17). While these effects
were initially exploited by the livestock industry, their use
quickly expanded to include body builders and athletes. In
more recent years, experimental interest has further expanded
to trial the treatment of a wide range of muscle-wasting
and neuromuscular diseases. In animal and human studies,
β2-adrenergic agonists have been reported to have a positive
but limited effect in dystrophic and injured muscle, as well as
in congenital myopathies and fascioscapulohumeral muscular
dystrophy (18–21). In addition, further studies have suggested
β2-agonistsmay have amodest effect in spinalmuscular atrophy,
and in denervated muscle following spinal cord injury (22,23).
It is in treatment of CMS however, that sympathomimetics
have demonstrated conclusive clinical benefit, and they now
comprise standard treatment for some subtypes of CMS
in the form of oral ephedrine or salbutamol (24). Several
observational studies demonstrate improvements in motor
symptoms and timed tests when CMS patients are administered
ephedrine or salbutamol and mobility may often improve to the
extent of regaining ambulation in wheelchair bound patients
(7,9–11,25–27). However, it is not known why treatments acting
via pathwaysmediated by the sympathetic nervous systemhave
therapeutic benefit in disorders of the NMJ. Despite its potential
implications in the understanding of both the pathogenesis
and treatment of many neuromuscular diseases, the effect of
β-agonists on the maturation and maintenance of NMJs has
never been clearly defined.
In order to address this, we have studied the effect of salbu-
tamol treatment on a model of end plate AChE deficiency, the
ColQ knockout (ColQ−/−) mouse. In these mice, endplate AChE
deficiency is caused bymutations not in ACHE itself but in COLQ,
which encodes the collagenic tail subunit bound to the catalytic
subunit in the asymmetric AChE found at the skeletal NMJ
(28,29). The N-terminal domain of ColQ anchors asymmetric
AChE to the synaptic basal lamina (30). In humans,mutations in
COLQ typically result in fatigable muscle weakness presenting
in the neonatal period or early infancy, often accompanied by
episodes of respiratory failure (31). The NMJs of these patients
have abnormalities in both the function (prolonged response to
ACh due to the absence of AChE activity) and structure (dis-
rupted postsynaptic apparatus, probably resulting from exces-
sive Ca2+entry into the muscle through the AChRs) (32,33).
Generally, these patients show either no long-term benefit or
worsening of symptoms with AChE inhibitors. However, treat-
ment with salbutamol and ephedrine has been shown to lead
to improved mobility and respiratory function in these patients
(25). ColQ−/− mice also lack all asymmetric AChE and exhibit
both muscle weakness and abnormalities of the NMJ (34,35),
thus closely resembling the human disease. In addition to its
role in anchoring AChE, ColQ binds to the key postsynaptic
organiser protein MuSK, and ColQ has also been shown to have
an important regulatory role in postsynaptic development and
maturation through this interaction (36–38). Given the clinical
improvement from salbutamol treatment in CMS patients is
gradual, requiring a period of weeks to months for full benefit,
we have tested the effects of long-term administration of salbu-
tamol, i.e. administered over a period of 7 weeks, in the ColQ−/−
mouse.
Here, we show that salbutamol treatment leads to a grad-
ual improvement in muscle strength in the ColQ−/− mouse.
In addition, we show that morphological defects of the NMJ
in the ColQ−/− mouse can be partially rescued by salbutamol
treatment, in ways which are likely to lead to enhanced neuro-
muscular transmission. These results provide new evidence for
the long-term effects of adrenergic signalling on the structural
properties of the NMJ.
Results
Salbutamol treatment improves muscle strength in
ColQ−/− mice
From 3 weeks of age, ColQ−/− mice received daily subcuta-
neous injections of salbutamol or vehicle control (water) for
7 weeks. Previous work has shown that ColQ−/− mice exhibit
muscle weakness which is apparent from P5 (34). We used fore-
limb grip strength to assess muscle strength at 3 time points
(Fig. 1A) in wild type (WT), ColQ−/− mice treated with water
and ColQ−/− mice treated with salbutamol. The performance of
water treated ColQ−/− mice was significantly worse than WT
littermates at baseline (3weeks old) and at subsequentmeasure-
ments (6 weeks old and 9 weeks old). In comparison, ColQ−/−
mice treated with salbutamol showed a gradual improvement
in grip strength, which became significantly better than water
treated ColQ−/− mice at 9 weeks (after 6 weeks of salbutamol
treatment) (water treated ColQ−/− 41.6±11.7 g vs. salbutamol
treated ColQ−/− 61.9±7.4 g (mean±S.D.)). ColQ−/− mice were
also smaller than WT littermates, having a body weight approx-
imately 50% that of littermates at 3 weeks (Fig. 1B) (34). This low
body weight persisted into adulthood, and was not altered by
salbutamol, with no significant difference in salbutamol treated
ColQ−/− mice body weight during 7 weeks of salbutamol treat-
ment (water treated ColQ−/− 21.3±2.71 g vs. salbutamol treated
ColQ−/− 19.5±2.13 g). In summary, salbutamol led to a gradual
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Figure 1. Salbutamol treatment improves muscle strength in ColQ−/− mice but does not alter body weight. A. Forelimb grip strength of WT, water treated ColQ−/−
(ColQ−/− WFI) and salbutamol treated ColQ−/− (ColQ−/− SAL) mice measured at 3, 6 and 9 weeks of age. Grip strength is significantly impaired in water treated
ColQ−/− mice compared to WT littermates at baseline, and at subsequent time points. Salbutamol treated ColQ−/− mice showed a tendency towards improved grip
strength after 3 weeks of treatment (6-wks-old) which became statistically significant after 6 weeks of treatment (9-wks-old). n =6 animals per group. Error bars depict
S.D. ∗∗ indicates P< 0.01. B. Growth curve demonstrating changes in body weight over 7 weeks of salbutamol treatment. ColQ−/− mice are significantly smaller than
WT littermates at all time-points and body weight is not affected by salbutamol treatment. n=6 animals per group.
improvement in limb muscle strength but did not affect body
weight in ColQ−/− mice.
Salbutamol treatment improves NMJ structural defects
in ColQ−/− mice
It has previously been shown that the ColQ−/− mouse exhibits
abnormal synaptic structure, including NMJs which appear frag-
mented or immature (34). We studied the pre and postsynaptic
morphology of NMJs from 10 week old ColQ−/− lumbrical mus-
cles and compared these to salbutamol treated ColQ−/− muscles,
using a standardised morphometric analysis platform (‘NMJ-
morph’) (39). ColQ−/− mice did demonstrate presynaptic struc-
tural defects, with small but significant decreases in axon diam-
eter (WT 3.49±0.79 μm vs water treated ColQ−/− 2.90±1.47 μm)
and nerve terminal area (WT 227.16±35.12 μm2 vs water treated
ColQ−/− 166.28±47.16 μm2) (Fig. 2B). These presynaptic defects
were not significantly different in salbutamol treated ColQ−/−
mice (axon diameter and nerve terminal area 2.96±1.43 μm and
159.42±33.89 μm2 respectively).
Postsynaptic morphology was more obviously perturbed in
the ColQ−/− mice (Fig. 2C-E and SupplementaryMaterial, Fig. S1),
with ColQ−/− lumbrical muscles showing significantly reduced
AChR area (WT 332.117±58.55 μm2 vs. water treated ColQ−/−
236.91±63.13 μm2) and reduced NMJ ‘compactness’ (derived
from (AChRArea/Endplate area) x100), ameasure of AChRdisper-
sal (WT 71.77±13.49% vs. water treated ColQ−/− 54.30±19.01%)
(39,40). These postsynaptic defects were significantly improved
in salbutamol treated mice (AChR area 303.52±75.69 μm2 and
compactness 76.23±22.26%).
Furthermore, the area of synaptic contact (the area of
contact between pre and postsynaptic NMJ components) was
significantly reduced in the ColQ−/− mice compared toWT litter-
mates (Fig. 2D) (WT 191.61±46.69 μm2 vs. water treated ColQ−/−
93.8±64.98 μm2), and this was increased by salbutamol treat-
ment (141.63±58.65 μm2). In keeping with previous studies, we
found the number of discrete fragments of AChR richmembrane
was significantly increased in the ColQ−/− mice (WT 2.88±0.93
fragments vs. water treated ColQ−/− 4.10±1.74 fragments). Frag-
mentation was not altered by salbutamol treatment, however
(3.91±1.00 fragments). We also examined these parameters in
soleus muscles (Supplementary Material, Fig. S1). Salbutamol
treatment also improved AChR area, compactness and area of
synaptic contact in soleus muscles, and we found no difference
in the magnitude of the effect of salbutamol in soleus muscle
compared to lumbricals (Supplementary Material, Fig. S1).
These results prompted us to examine whether the fluores-
cence intensity per μm2 of α-BTX, a measure of the local AChR
density, was different in salbutamol treated mice. In lumbricals
fromwater treated ColQ−/− mice,AChR densitywas significantly
reduced compared to WT littermates (mean pixel intensity per
μm2 WT 255.39±149.49 vs.water treated ColQ−/− 119.68±69.49).
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/14/2339/5424977 by guest on 05 July 2019
2342 Human Molecular Genetics, 2019, Vol. 28, No. 14
Figure 2. Salbutamol treatment improves postsynaptic NMJ morphology in ColQ−/− mice. A. Representative confocal micrographs of NMJs in the lumbrical muscles
of 10-wk-old WT, water treated ColQ−/− (ColQ−/− WFI) and salbutamol treated ColQ−/− (ColQ−/− SAL) mice, labelled with anti-neurofilament (red) and anti-
synaptophysin (red, both NT) and Alexa fluor 488 α-bungarotoxin (green, AChR).Water treated ColQ−/− mice display variable NMJ morphology with smaller NMJs with
reduced AChR density. Scale bar, 10 μm. B.Quantitative analysis of presynaptic variables from lumbrical muscles. ColQ−/− mice exhibited smaller nerve terminals with
thinner axons, and these variables were unchanged in salbutamol treated mutants. C. Quantitative analysis of postsynaptic variables from lumbrical muscles. Water
treated ColQ−/− mice had reduced AChR area and compactness, which were significantly increased in salbutamol treated ColQ−/− mice compared to water treated
ColQ−/− mice.D.Quantitative analysis of area of synaptic contact. ColQ−/− mice have significantly reduced area of synaptic contact which is increased by salbutamol
treatment but remains smaller than in WT animals. E. Quantitative analysis of fragmentation of NMJs. ColQ−/− NMJs exhibit significantly increased number of AChR
rich fragments per NMJ, and this was not different in salbutamol treated animals. n=180 NMJs analysed per group for B-E. Analysis of NMJ-morph variables from soleus
muscle are provided in Supplementary Material, Figure S2. F. Quantification of α-bungarotoxin fluorescence intensity of individual NMJs measured from projection
of confocal stacks from lumbrical muscles. Fluorescence intensity was significantly decreased in water treated ColQ−/− mice, and was significantly increased in
salbutamol treated ColQ−/− mice compared to water treated ColQ−/− mice. n=120 NMJs analysed per group for F. All error bars depict S.D. Unpaired Student’s t tests.
∗∗∗∗p< 0.0001, ∗∗∗p< 0.001, ∗∗p< 0.01, ∗p<0.05.
In comparison, in salbutamol treated ColQ−/− lumbricals, AChR
density was significantly increased compared to water treated
ColQ−/− mice (mean pixel intensity per μm2 211.89±139.41).
Together, these observations suggest that salbutamol treat-
ment can alter NMJ structural defects in ColQ−/− mice, and in
particular increase AChR area, synaptic area and AChR density.
Salbutamol alters ultrastructural appearances of the
postsynaptic membrane
In mature NMJs, the postsynaptic membrane is invaginated
with extensive folds extending into the postsynapticmembrane,
which amplify the transmitter action of ACh (41). AChRs accu-
mulate at the crests of these postjunctional folds, which can
be visualised at the EM level by electron dense material at the
top of the folds and extending partly down the folds (42). Under
the electron microscope, many NMJs from intercostal muscles
of 10 week old water treated ColQ−/− mice appeared normal, as
has been previously reported in 6 month old ColQ−/− mice (34).
However, in 50% of NMJs the extent of folding appeared clearly
reduced and regions of high electron-density at the crests of
folds were lost (Fig. 3A). We quantified the extent of postjunc-
tional folding using fold index (total surface length of postsynap-
tic membrane measured along the tops of the folds/total length
of postsynaptic membrane including folds) a measure of the
increase in postsynaptic membrane area resulting from folding
(43). This revealed a significant reduction in extent of folding in
ColQ−/− mice compared to WT (mean fold index WT 4.28±1.38
vs. water treated ColQ−/− 2.50±0.72) (Fig. 3B). In addition, in
salbutamol treated ColQ−/− mice, fold index was significantly
increased compared to water treated ColQ−/− mice (3.65±1.03).
Additional features measured from EM images are provided in
Supplementary Material, Table S1.
Immunoreactivity of Agrin, Dystroglycan and MuSK in
ColQ−/− mice
The effects of salbutamol on postsynaptic structural defects
prompted us to explore the effect of salbutamol on MuSK, agrin
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Figure 3. The extent of postjunctional folding is increased in salbutamol treated ColQ−/− mice. A. Representative electron micrographs of sections through single
boutons from intercostal muscles of 10-wk-old WT, water treated ColQ−/− (ColQ−/− WFI) and salbutamol treated ColQ−/− (ColQ−/− SAL) mice. NT: nerve terminal,
PJ: postjunctional folds, SC; Schwann cell. In WT mice, the postsynaptic membrane is extensively infolded and AChRs can be seen as areas of high electron-density at
the crests of the folds (arrows). In ColQ−/− mice, the appearance of increased membrane density at the tops of the folds is lost, the extent of folding is reduced and the
synaptic space appears widened (stars, right panel) although some NMJs appear normal (left panel). Salbutamol treated ColQ−/− NMJs exhibit similar ultrastructural
appearances toWT littermates. Scale bar 0.5 μm. B. Quantitative analysis of changes in the extent of folding with salbutamol treatment. In salbutamol treated ColQ−/−
mice, the extent of postjunctional folding is significantly increased compared to water treated ColQ−/− mice, as measured by fold index (fold length/postsynaptic
length). n≥ 15 boutons from three mice analysed per group. Mann Whitney U test. ∗∗∗∗p<0.0001, ∗∗p<0.01.
and α-dystroglycan. MuSK provides the primary scaffold for
AChR clustering and postsynaptic differentiation (44). The C-
terminus of ColQ binds MuSK and ColQ deficiency leads to
reduced levels of membrane bound MuSK (36,37). The glycopro-
tein agrin is secreted by motor axon terminals to activate the
LRP4/MuSK/Dok7 complex to induce and stabilise AChR clusters
(45). Dystroglycan, a component of the dystrophin associated
glycoprotein complex (DGC), is essential for the assembly of
a synaptic basement membrane, and linking the extracellular
matrix to the cytoskeleton (46). ColQ binds to perlecan which
in turn binds α-dystroglycan, and this interaction is necessary
for the synaptic localisation of AChE (47). In addition, the local-
isation of AChRs at the crests of the folds arises through their
interaction with the DGC (48).
In order to determine membrane bound MuSK protein
levels, we analysed MuSK fluorescence intensities per AChR
cluster in transverse sections of gastrocnemius muscle from
WT, water treated ColQ−/− and salbutamol treated ColQ−/−
mice (Fig. 4A). MuSK fluorescence intensity was significantly
reduced in water treated ColQ−/− mice compared to WT (mean
MuSK-to-α-BTX fluorescence intensity ratio WT 0.76±0.21 vs.
water treated ColQ−/− 0.44±0.06). In salbutamol treated ColQ−/−
muscle, the MuSK-to-α-BTX fluorescence intensity ratio was
increased compared to water treated ColQ−/− mice (Fig. 4B,
mean MuSK-to-α-BTX fluorescence intensity ratio 0.55±0.12
in salbutamol treated ColQ−/− mice). In contrast to MuSK
staining, the fluorescence intensity of agrinwas not significantly
different in either water treated ColQ−/− or salbutamol treated
ColQ−/− mice compared to WT animals (data not shown). In
addition, the distribution and intensity of immunostaining of
α-dystroglycan was qualitatively similar in ColQ−/− and WT
mice, and was not affected by salbutamol treatment (data not
shown).
Salbutamol treatment does not alter muscle fibre area
or fibre type composition in ColQ−/− mice
It has previously been shown that ColQ−/− mice exhibit both
reduced muscle fibre diameter and alteration of fibre type com-
position (35,38). We therefore examined the effect of salbu-
tamol treatment on these parameters. At 10 weeks, muscle
fibre cross sectional area in water treated ColQ−/− mice was
significantly reduced in both gastrocnemius (mean cross sec-
tional area WT 1740±434.73 μm2 vs. water treated ColQ−/−
1342±317.51 μm2) and soleus (WT 1188±105.4 μm2 vs water
treated ColQ−/− 781±185.44 μm2). Muscle fibre area was not
significantly different in salbutamol treated ColQ−/− mice com-
pared to water treated ColQ−/− mice (Fig. 5A and B) (mean cross
sectional area 1308±350.45 μm2 and 802±217.51 μm2 in gas-
trocnemius and soleus muscles respectively). In addition, exam-
ination of fibre type composition in gastrocnemius and soleus
muscles revealed a dramatic reduction inMHC type 1 expressing
fibres in both muscles, as well as an increase in MHC type 2A
fibres in water treated ColQ−/− mice. Again, these changes in
fibre type compositionwere unaffected by salbutamol treatment
(Fig. 5C-F). These data indicate that the effect of salbutamol on
NMJ structure and on grip strength in the ColQ−/− mouse is not
secondary to changes in skeletal muscle trophism.
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Figure 4. Salbutamol treatment alters MuSK immunoreactivity in ColQ−/− mice. A. AChR and MuSK clusters labelled with Alexa 488 α-BTX (green, AChR) and anti-
MuSK antibody (red) respectively on transverse sections of gastrocnemius muscle from 10-wk-old WT, water treated ColQ−/− (ColQ−/− WFI) and salbutamol treated
ColQ−/− (ColQ−/− SAL) mice. Scale bar, 20 μm. B.Quantification of MuSK fluorescence intensities from projection of confocal stacks. MuSK fluorescence intensity per
AChR cluster was decreased in ColQ−/− muscle, and significantly increased in salbutamol treated ColQ−/− mice compared to water treated. n=180 NMJs per group
for B. Unpaired Student’s t tests. ∗∗∗p< 0.001, ∗p< 0.05, n.s. not significant.
Immunoreactivity of β2 adrenoceptors colocalises with
the NMJ in WT and ColQ−/− mice
Salbutamol is a selective ADBR2 agonist, and it has been previ-
ously shown that ADBR2 is the predominant adrenoceptor sub-
type in skeletal muscle (49,50). In order to investigate the distri-
bution of ADBR2 on themusclemembranewe stained transverse
sections of gastrocnemius muscle with ADBR2 antibody and α-
BTX (Fig. 6A). This revealed co-localisation of ADBR2 immunore-
activity at the NMJ. In addition, this pattern of immunostaining
did not appear to be altered in ColQ−/− mice andwas not affected
by 7 weeks of salbutamol treatment (Fig. 6B).
Discussion
Our study provides evidence that treatment of AChE-deficient
ColQ−/− mice with the sympathomimetic salbutamol, over a
period of weeks, partially normalises both their weakness of
grip strength and the structural abnormalities of NMJs that
may help to explain that weakness. It has long been suspected
that activation of adrenergic receptors can alter neuromuscular
transmission. In vitro, ephedrine increases quantal content, and
ephedrine and salbutamol block the AChR channel, although
only when applied at higher concentrations than obtained at
therapeutic doses in humans (51,52). In addition, adrenaline and
noradrenaline can potentiate neuromuscular transmission, and
activation of α1 and β adrenoceptors has been shown to enhance
nerve evoked ACh release (53–55). However, these immediate
effects do not account for the delayed therapeutic action of
salbutamol in patients with CMS, which suggest an additional
longer term modulation of NMJ function. There is, however,
increasing evidence for the role of the sympathetic nervous
system in maintenance of the NMJ. Recent studies demonstrate
that NMJs are intimately linked to a network of sympathetic
neurons within skeletal muscle which increase during postnatal
development, a network which is critical for the morphological
integrity of the NMJ (56,57). We previously showed that salbu-
tamol rescued aberrant NMJ development in zebrafish embryos
lacking Dok7 and MuSK (58). Here, in a setting more closely
resembling human disease and treatment regimens, we show
that long-term administration of salbutamol leads to functional
benefit and improves postsynaptic structural defects in amouse
model of end plate AChE deficiency.
Salbutamol treatment resulted in a significant increase in
grip strength of ColQ−/− mice. This effect was gradual, becoming
significantly better only after 6 weeks of daily administration.
This mirrors the effect in humans with ColQ CMS where, unlike
the rapid clinical benefit seen from AChE inhibitors in other
forms of CMS, the response to sympathomimetics is more grad-
ual with an increasingly positive response over 3–6 months of
treatment (11,59). As previously reported, the phenotype of the
ColQ−/− mouse is not as severe as would be expected from
a complete lack of AChE. Interestingly, in both the salbuta-
mol treated and water treated ColQ−/− mice, grip strength was
improved at 9 weeks compared to 3 weeks. In previous studies
of the ColQ−/− mice, NMJ abnormalities also appeared to lessen
with age, suggesting a compensatory mechanism (34). These
studies suggested that capping of the motor nerve terminal by
the Schwann cell serves to protect the end-plate from lost ACh
clearance (34,60). However, invasion of the synaptic cleft by the
Schwann cell was not a feature in any of the NMJs examined
with EM in this study. The findings may reflect the homeostatic
plasticity of the NMJ, as occurs in response to trauma, toxins
and in autoimmune myasthenia gravis (41,61,62). The precise
processes underlying adaptive plasticity in the ColQ−/− mouse
have not yet been determined.
The effects of β-adrenergic agonists on skeletal muscles are
known to include muscle fibre hypertrophy and alteration of
fibre type composition (63–65). The ColQ−/− mouse exhibits
features of muscle atrophy,with reduction in type I and increase
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Figure 5. Alterations in muscle fibre diameter and type in ColQ−/− mice are not affected by salbutamol treatment. A, B: Frequency distributions of muscle fibre cross
sectional area from 10-wk-old WT, water treated ColQ−/− (ColQ−/− WFI) and salbutamol treated ColQ−/− (ColQ−/− SAL) gastrocnemius (A) and soleus (B) muscles.
Plots represent percentage of fibres in each size bin. Fibres are significantly smaller in ColQ−/− muscles compared with those in WT fibres (Mann-Whitney U test) but
fibre diameter was unaffected by 7 weeks of salbutamol treatment. n=6 muscles per genotype, with ≥500 muscle fibres sampled to generate the size distributions.
∗∗∗p< 0.001, ∗p< 0.05 C—F: Fibre type composition in WT and ColQ−/− muscles. Transverse sections of gastrocnemius (C) and soleus (E) muscles from 10-wk-old WT
and ColQ−/− animals, stained with anti-laminin (green), to delineate the fibre circumference and MHC Type 1 (blue), Type IIa (red) and Type IIb (green). ColQ−/− mice
exhibit significantly fewer Type 1 fibres and increased Type 2A fibres in both gastrocnemius (D) and soleus (F) muscles, which was not affected by 7 weeks of salbutamol
treatment. Scale bar, 50 μm.
in type IIA fibres as well as reduced fibre size (38). It is plausible
therefore, that adrenergic agonists lead to clinical benefit in ColQ
CMS due to promotion of muscle growth. However, our analysis
of fibre type composition and area in both soleus and gastrocne-
mius muscles revealed no detectable effect of salbutamol treat-
ment on anyparametermeasured inColQ−/− mice.This suggests
that the improved grip strength in salbutamol treated ColQ−/−
animals cannot be readily explained by an anabolic effect on
skeletal muscle. This is consistent with the lack of evidence of
clinical benefit of sympathomimetic treatment in myopathies
and muscular dystrophies (20,21,66,67). Since both the structure
and function of the NMJs is abnormal in ColQ−/− mice (34), we
turned our attention to the possibility that salbutamol may act
to enhance muscle activation by action on the NMJs.
In support of this view, we found evidence of a partial nor-
malisation of synaptic area, local AChR density and the extent
of postsynaptic folding in salbutamol treated ColQ−/− mice, all
changes which would be likely to enhance the efficacy of neu-
romuscular transmission. Using standardised analysis of NMJs
(39), we confirmed pronounced defects in the structure of the
NMJs in water treated ColQ−/− mice which are likely to be asso-
ciated with a decreased efficacy of neuromuscular transmission
(34,35). These involved changes to both presynaptic and postsy-
naptic components of the NMJ. On the presynaptic side, there
was a modest reduction in both the terminal axon diameter
and nerve terminal area. There was also a significant reduction
in the area of overlap between the nerve terminal and the
underlying region of high AChR density (‘synaptic area’). There
is an approximately linear relationship between synaptic area
and quantal content, and a pathological reduction in synaptic
area has been demonstrated in patients with ColQ CMS, and
in CMS due to mutations in the postsynaptic adaptor DOK7
(60,68,69). Therefore, any reduction in synaptic area is likely to
be associated with reduced quantal content and the efficacy of
neuromuscular transmission.
On the postsynaptic side, we found that at 10 weeks of age,
the labelling intensity of AChRs was strikingly reduced in water
treated ColQ−/− mice, suggesting a reduced local AChR density at
theNMJs.Any reduction in local AChRdensitywould be expected
to reduce the number of AChRs opened by individual transmitter
quanta and thus impair neuromuscular transmission. However,
previous studies of ColQ−/− mouse showed an increased AChR
density in sternomastoid and soleusmuscles at 7 days of age (36).
These divergent findings may be due to differences in the age of
themice examined, given that at postnatal day 7mouseNMJs are
still undergoing structural and molecular maturation and AChR
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Figure 6. β2 adrenergic receptor immunostaining co-localises with the NMJ.A.Transverse sections of gastrocnemiusmuscle from 10-wk-oldWTmice stainedwith anti-
ADBR2 antibody (red) and Alexa 488 α-BTX (green, AChR). ADBR2 staining is enriched at the NMJ. Scale bar, 20 μm. B. Quantification of ADBR2 fluorescence intensities
per AChR cluster from projection of confocal stacks. ADBR2 fluorescence intensity per AChR cluster was not significantly different betweenWT,water treated ColQ−/−
or salbutamol treated ColQ−/− mice. Unpaired Student’s t tests.
richmembrane is not yet fully restricted to regions ofmotor axon
contact (70). AChR deficiency has also been shown in ColQ CMS
patients (60). In parallel with the reduction of AChR density, we
found a decrease in the area occupied by a high density of AChRs.
This extends previous studies showing reduced AChR area in
adult (diaphragm, levator auris longis) and 7 days old (soleus and
sternomastoid) ColQ−/− mice (35,36).
A likely explanation for reduced AChR density at the NMJ is
the simplification and disorder of the postsynaptic folds asso-
ciated with AChE deficiency (32). Since a substantial fraction
of AChRs are normally present in the membrane of the folds
closest to the nerve, any disruption of membrane folding may
result in reduced numbers of AChRs as detected by fluorescence
microscopy. Consistent with this view, our preliminary analysis
of NMJs from intercostal muscles of ColQ−/− mice confirmed the
significant reduction in the extent and orderliness of postjunc-
tional folds. The high density of voltage-gated sodium channels
in the depths of the folds is believed to facilitate initiation of
the muscle fibre action potential (69,71), suggesting a second
way in which the reduced folding in ColQ−/− mice may impair
neuromuscular transmission.
Treatment of ColQ−/− mice with salbutamol for 7 weeks
resulted in a partial normalisation of a number of the abnor-
malities of NMJ structure which are likely to be associated with
impaired NMJ function, particularly those associated with the
postsynaptic component. These include the area of synaptic
contact, the local AChR density and the extent of folding, with
similar degrees of effect found in lumbrical and soleus muscles.
Whilst electrophysiological studies will be required in order
to confirm that these structural alterations are coupled with
improved NMJ function, the changes are likely to have important
implications for the efficiency of neuromuscular transmission
(41,72–74). Our findings of pronounced postsynaptic structural
effects from salbutamol are in keeping with the fact that it is the
CMS subtypes with predominant postsynaptic alterations which
show greatest clinical benefit from salbutamol and ephedrine
(4,7,11,75).
The differentiation of the postsynaptic region at the NMJ is
strongly influenced by the activity of MuSK (44). ColQ deficiency
has been shown to regulate membrane bound MuSK, and to
subsequently lead to decreased signalling of MuSK as measured
by reduced phosphorylation of the β-AChR subunit (36). This
led us to ask whether salbutamol treatment might enhance
the expression of membrane bound MuSK in ColQ−/− mice.
We observed reducedMuSK immunoreactivity in gastrocnemius
muscle from untreated ColQ−/− mice, and this was significantly
increased by salbutamol treatment. It is not possible to say
whether salbutamol alters the activity of the MuSK signalling
pathway, or whether this finding is secondary to improved post-
synaptic architecture in salbutamol treated muscles. Further
studieswill be required to determinewhether salbutamol affects
MuSK phosphorylation and kinase activity.
The distribution of ADBR2 on skeletal muscle membrane has
not been previously well described. Here we observed ADBR2
immunostaining precisely co-localising with AChRs in gastroc-
nemius muscle from both WT and mutant adult mice, similar to
the patterns previously observed in one study ofmouse extensor
digitorum longus muscle (56). This co-localisation is intriguing
and further suggests that ADBR2 and their signalling compo-
nents have an important contribution to NMJ function.
In some cases of CMS, the clinical benefit from salbutamol
seems to attenuate after years of treatment (unpublished
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observations). This may be due to desensitisation of ADBR2 after
chronic agonist administration, as occurs when β2-adrenergic
agonists are used in the treatment of chronic heart failure and
asthma, although this has not been confirmed in CMS (76,77).
The development ofmore targeted therapies for CMS,potentially
those which act downstream of ADBR2, are therefore essential
to improve quality of care.We previously showed that the effects
of salbutamol at NMJs of zebrafish embryos could be blocked by
a selective ADBR2 antagonist, and could be replicated by directly
increasing cyclic AMP with forskolin (58). Identification of the
cellular processes which are regulated by the cAMP and the
cAMP-dependent protein kinase (PKA) signalling pathway at the
NMJ is required for the identification of possible therapeutic
targets.
Postsynaptic differentiation is controlled by factors released
frommotor nerves, glial cells and by intrinsic muscle signalling.
There are thus a multitude of pathways through which acti-
vation of ADBR2 receptors and the cAMP signalling pathway
could lead to improved postsynaptic NMJ morphology (78,79).
Nonetheless, our observations in the ColQ−/− mouse provide
further evidence for important interplay between the NMJ and
adrenergic signalling pathways. An understanding of the effect
of sympathomimetics at the NMJ will be instrumental in order
to facilitate the development of more targeted therapies, which
benefit NMJ function whilst minimising systemic side-effects.
Materials and Methods
Mice
All procedures were approved by the Home Office and were
carried out in accordance to the Animals Scientific Procedures
Act of 1986 under project licence 70/8538. The generation of
the ColQ−/− mouse was described by Feng et al (34). ColQ+/−
mice were donated by the Krejci laboratory, COGNAC G cognition
action group, Université Paris Descartes. Mice were bred and
housed in the animal facility at the Functional Genomics Unit,
Institute of Genetic Medicine, Newcastle University.
Drug treatment of mice
From post-natal day 21, ColQ−/− mice received daily subcu-
taneous injections for 7 weeks of either Salbutamol (α-[(tert-
Butylamino)methyl]-4-hydroxy-m-xylene-α,α′-diol, Albuterol;
Sigma) diluted in water for injection (n=6 animals) or the
equivalent volume of water alone (n=6 animals). Injections
were delivered into the loose skin over the interscapular area.
Salbutamol was administered at a dose of 5 mg/kg which is
equivalent to doses used in the treatment of CMS patients
(59). Mice were weighed prior to injection daily. Wild type
(WT) littermates were weighed and inspected daily in a similar
manner to injected littermates. Researchers handling the
animals were blinded to the genotype and drug allocation of
each animal. Animals were weighed and inspected daily for
signs of drug toxicity or side effects, and no adverse effects were
observed. All mice were sacrificed within six hours of the last
injection at 10 weeks of age.
Forelimb grip strength test
An electronic grip strength meter (Bioseb) was used to deter-
mine the maximal peak force of the forelimbs (80). Mice were
allowed to grasp the grid and were pulled horizontally by the
tail until the grip was released. The pull force was measured
when the pulling force overcame the mouse’s forelimb grip
strength. Testing was performed in six animals per group at
three time points—3 weeks, 6 weeks and 9 weeks of age. Three
measurements were performed per mouse during each test and
the average of these threemeasurementswas used for statistical
evaluation. These experiments were conducted in a blinded
fashion by the same experimenter, 5 hours after injection.
Whole-mount muscle staining
Whole soleus and hindlimb lumbrical muscles from 10 week old
mice were dissected, washed in phosphate buffered saline (PBS)
for 30 minutes, and then fixed (1% paraformaldehyde in 0.1 M
PBS) for 10minutes before being teased into small bundles. After
teasing, muscles were fixed in 1% PFA overnight at 4 ◦C. Muscles
were permeabilised in ethanol followed by methanol (10 min at
−20 ◦C each), followed by an incubation/permeabilisation step
in 5% horse serum, 5% BSA, 2% Triton X-100 (for 4 hours at room
temperature).Muscleswere incubated overnightwith antibodies
against neurofilament (mouse monoclonal anti-neurofilament,
1:200, Cell Signalling technology), and synaptophysin (rabbit
polyclonal anti-synaptophysin, 1:100, Thermo Fisher Scientific)
or against agrin (mouse polyclonal anti-agrin, 1:250, Abcam) in
PBS containing 5% horse serum, 5% BSA. The next day muscles
were washed in PBS containing 5% horse serum, 5% BSA for four
hours and then incubated in Alexa Fluor® 488 α-bungarotoxin
(α-BTX) (1:250, Thermo Fisher Scientific), Alexa Fluor® 568 goat
anti-mouse (1:250, Thermo Fisher Scientific) and Alexa Fluor®
594 goat anti-rabbit (1:250, Life Technologies) overnight. The
following day muscles were washed in PBS for 4 hours and
then mounted on slides with Vectashield mounting medium for
fluorescence microscopy (Vector Laboratories).
NMJ imaging and analysis
Samples were visualised using a Nikon A1R laser scanning
confocal microscope. Laser power and parameter settings
were kept constant and Z-stack images (1-μm intervals) were
acquired with x63 oil immersion objective and processed
using NIS-elements AR 4.20.02 software. Soleus and lumbrical
muscles from 6 mice per group were imaged; ≥30 NMJs were
analysed per muscle. Variables for NMJ structural analysis
were measured from maximum intensity Z-stack images using
the ‘NMJ-morph’ protocol on ImageJ as described previously
(39). For quantitation of AChR density, confocal micrographs
of control and experimental mice were collected in the same
session permitting comparison of fluorescence intensity. AChR
density was performed only on lumbrical muscles on which
NMJs could be visualised relatively quickly. The perimeters
of clusters were delimited and the area and average pixel
intensity calculated using ImageJ software. The AChR cluster
outline was then placed in an adjacent area without clusters
to record background fluorescence intensity. This reading was
subtracted from the cluster reading, to give a background-
corrected intensity. Lumbrical muscles from six mice per group
were imaged; ≥20 NMJs were analysed per muscle.
Immunostaining on sections
Immunostaining of ADBR2, MuSK and α-dystroglycan was
performed on 10 μm transverse sections of gastrocnemius
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muscle cut using a cryostat (Microm HM 560, Zeiss) in the region
of the motor end-plate. Sections were fixed in acetone at 4 ◦C
for 15 minutes and then permeabilised in 0.1% Triton X-100
for 15 minutes at room temperature. Sections were blocked in
PBS containing 10% goat serum, 1% BSA for 30 minutes and
then incubated with primary antibody (rabbit anti-MuSK 1:500,
Abcam; rabbit anti-ADRB2 1:200; Santa Cruz Biotechnology;
mouse anti-α-dystroglycan 1:100; Santa Cruz Biotechnology) in
blocking buffer for 2 hours at room temperature. Sections were
washed and incubated in Alexa Fluor® 488 α-BTX (1:250), and
secondary antibodies Alexa Fluor® 594 goat anti-rabbit (1:250)
for 1 hour at room temperature. Sections were then washed and
mounted using Vectashield mounting medium.
Quantification of MuSK, agrin and ADBBR2 staining
intensity
Quantification of relative staining intensities was performed as
described previously (36,81). Transverse sections of gastrocne-
mius (MuSK and ADBR2 staining) or whole mounts of lumbrical
muscles (agrin staining) were visualised using a Nikon A1R
laser scanning confocal microscope. Laser power and parameter
settings were kept constant and Z-stack images (1-μm intervals)
were acquired with x63 oil immersion objective and processed
using NIS-elements AR 4.20.02 software. Confocal micrographs
of control and experimentalmicewere collected in the same ses-
sion. Quantification of relative area and fluorescence intensity
of α-BGT to MuSK, agrin or ADBR2 was performed using ImageJ
software.The perimeters of clusterswere delimited on the α-BGT
channel and the area and fluorescence intensity measured. This
selection was restored in the Alexa Fluor® 594 channel and the
area and fluorescence intensity of MuSK, agrin or ADBR2 was
measured. The background intensity in each channel was sub-
tracted from the pixel intensity of the protein of interest, and the
background-corrected intensity for each channel were divided
to give a MuSK/agrin/ADBR2-to-α-BGT fluorescence intensity
ratio. For MuSK and ADBR2 fluorescence intensity, gastrocne-
mius muscles from six mice per group were imaged; ≥40 NMJs
were analysed per muscle. For agrin fluorescence intensity, lum-
brical muscles from six mice per group were imaged and 20
NMJs were analysed per muscle. All imaged AChR clusters were
measured.
Fibre type identification
Transverse 10 μm sections of soleus and gastrocnemiusmuscles
were cut using a cryostat and labelled for Myosin Heavy Chains
(MHC) MHCI, MHCIIa, and MHCIIb and MHCIIx. Sections were
blocked (10% normal goat serum in PBS) for 1 hour at room
temperature and then incubated with primary antibodies: rabbit
polyclonal IgG anti-laminin (Sigma 1:750), MHCI (BA-F8 Mouse
monoclonal IgG2b) 1:25, MHCIIa (Sc71, Mouse monoclonal IgG1),
MHCIIb (BF-F3 Mouse monoclonal IgM) 1:200 and MHCIIx (6H1
Mouse monoclonal IgM) 1:25, all DSHB, for 1 hour at room tem-
perature. Sections were then washed in PBS and incubated in
secondary antibodies for 1 hour, washed and mounted using
Vectashield mounting medium. Images were captured using a
Zeiss Axio Imager fluorescentmicroscopewith Zen software and
analysed using ImageJ software. In each section, every adjacent
field was examined moving from left to right in a systematic
manner until the required number was reached. Cross-sectional
areas and fibre type proportions were measured in 500 fibres
from six non-over-lapping fields at x40 view from six muscles
per group.
Transmission electron microscopy
Fresh tissue samples of intercostal muscles were fixed in 2% glu-
taraldehyde (TAAB Lab), osmicated in 1%osmium tetroxide (Agar
Scientific), dehydrated and embedded in epoxy resin (Epoxy
embedding resin kit, TAAB Lab). Semi-thin survey sections of
0.5 μm were cut and stained with 1% toluidine blue in 1% borax.
Ultrathin sections (70 nm approximately) were then cut and
stainedwith 2% aqueous Uranyl Acetate and Lead Citrate (Leica).
The grids were examined on a Hitachi HT7800 transmission
electron microscope using an Emsis Xarosa camera with Radius
software. Four intercostal muscles from three animals of each
group (salbutamol treated ColQ−/−, water treated ColQ−/− or
WT) were subjected to EM analysis. Quantitative analysis was
done with 15 or more electron micrographs analysed by ImageJ.
At each distinct region of postsynaptic folding the following
features were measured, as described by Slater et al (43): nerve
terminal area (total area of axon terminal); presynaptic length
(total length of the nerve terminal in direct contact with the
muscle fibre); postsynaptic area (total area containing postsy-
naptic folds); postsynaptic length (total surface length of sub-
neural apparatus measured along the tops of the folds); fold
length (total length of postsynaptic membrane including folds);
fold number (the number of distinct postsynaptic folds). These
measurementswere used to calculate the following derived vari-
ables: (i) Occupancy (presynaptic length/postsynaptic length);
(ii) fold index (fold length/postsynaptic length); (iii) fold density
(fold length/postsynaptic area).
Statistical analysis
Data are expressed as means ± S.D. unless otherwise stated.
Statistical analyses were performed using GraphPad Prism Ver-
sion 7 (GraphPad, San Diego, CA, USA) by pair-wise comparisons
between 2 conditions with unpaired Student’s t tests or Mann-
Whitney U tests. We confirmed normal distributions of data
before performing parametric tests using theD’Agostino Pearson
omnibus normality test. P<0.05 denoted significance. Datasets
were tested for outliers using the ROUT method (robust regres-
sion and outlier removal; Q = 1%). None of the outliers affected
statistical significance and all were included in analysis. Images
were analysed in a blinded fashion by the same experimenter.
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